Vernalis in $100m deal for new Parkinson's drug
Friday 25 June 2004
Vernalis, the former British Biotech, has licensed its innovative new Parkinson's disease pill to a US company for up to $100m (£55m) - one of the biggest deals in the biotech sector this year.
Biogen Idec, the US biotechnology giant, is paying an initial $10m for the drug and paid a further $6m for new Vernalis shares, staving off a cash crisis at the historic UK company.
Vernalis has completed just one set of trials of the Parkinson's drug, codenamed V2006, but it shows promising results in stimulating the production of dopamine, the chemical in the brain whose loss leads to Parkinson's.
Simon Sturge, the chief executive, said the deal transferred the costs of future trials over to Biogen, although Vernalis keeps an option to co-market V2006 if the company has created a salesforce by the time the drug reaches the market, towards the end of the decade.
He said: "We don't have to now make the investment in the clinical development but, in the event it is successful, we can then participate in the marketing of it. We have also agreed double-digit percentage royalties. These are exceptional deal terms for something that is so early in development."
Vernalis shares leapt 16 per cent to 55.5p. They had previously fallen to within pennies of a record low because the company said in March that it was planning a rights issue.
It needs extra cash to pay for the acquisition of marketing rights to its only launched product, the migraine pill Frova, and for further trials of the drug. Ireland's Elan had originally bought the rights to Frova but sales had proved disappointing and Vernalis bought Elan out of the deal for $50m. The first $20m payment is due by the end of the year.
Mr Sturge said Vernalis was already in detailed discussions with several drug firms over re-licensing Frova.
Jonathon Senior, an analyst at Evolution Beeson Gregory, said: "While the $16m will not cover the entire cost of Frova, it does provide Vernalis some flexibility in terms of the nature and the timing of a fund raising. In addition, it strengthens the company's position in negotiations with other businesses concerning the relicensing of the Frova rights."
Biogen has agreed to buy a further $4m new shares when Vernalis launches an equity fund raising and Mr Sturge promised a resolution to the company's funding difficulties soon. "It is our goal to secure the long-term financial position of the company in the next two or three months," he said.
- 1 Forget 'The Dress': Here are five of the biggest news stories you might have missed
- 2 The black and blue dress: Makers considering a white and gold version
- 3 Prince Harry leaving the armed forced to pursue conservation projects in Africa
- 4 PornHub turns masturbation into energy in bid to save the planet
- 5 The remarkable archaeological underwater discovery that could open up a new chapter in the study of European and British prehistory
Boris Nemtsov shot dead: Outspoken Putin critic who had expressed fears for his life is killed near the Kremlin
Leonard Nimoy dead: Star Trek Spock actor dies after suffering lung disease
PornHub turns masturbation into energy in bid to save the planet
Ukraine crisis: Top Chinese diplomat backs Putin, says West should 'abandon zero-sum mentality'
White and gold or blue and black – what colour is the dress? An eyewitness gives a definitive answer
New theory could prove how life began and disprove God
Half of Ukip voters say they are prejudiced against people of other races
'Cash for access' scandal: Sir Malcolm Rifkind says 'unrealistic' for MPs to live on £67,000 salary
This is what it's like to be dead, according to a guy who died for a bit
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Aqsa Mahmood branded a 'disgrace' by her parents after claims she recruited three UK girls flying to Middle East
iJobs Money & Business
£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...
£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...
£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...
£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...